ECG-derived machine-learning models provide a cost-effective strategy for predicting echocardiographically defined patients subgroups at a high-risk of MACE and may aid in optimizing intervention strategies.
HeartSciences’ AI-ECG products are currently in development and not commercially available in the United States.
wavECG and wavEKG are trademarks of HeartSciences.
MV-WBSTE-002 Rev A